Akt Activation With IPL344 Treatment for Amyotrophic Lateral Sclerosis: First in Human, Open-Label Study

Neurofi lament light chain level change in plasma of ALS patients following IPL 344 treatment in phase 1/2a clinical trial (NCT03652805, NCT03755167)

Peptide IPL344, an AKT activator, treats SOD1 ALS model mice to improve neuromuscular function

Treatment with IPL344, an Akt activator, improves neuro-muscular function in SOD1G93A ALS model mice

Proceedings of the 21st Annual Meeting of the Northeast ALS Consortium

First in human phase 1/2a open label study evaluating the safety and efficacy of the Akt activator, IPL344 in amyotrophic lateral sclerosis

Activation of the Akt–CREB signalling axis by a proline-rich heptapeptide confers resistance to stress-induced cell death and inflammation